The two primary goals of a pharmacy benefit manager or pharmacy benefit administrator are simple: contain cost and improve outcomes. Outcomes must include safety. If a pharmacy program saves money while exposing members to avoidable risk, it is not well managed. If it improves access but ignores waste, duplicate therapy, poor adherence, inflated drug selection, or unsafe utilization, it is not well managed either.

Cost containment and outcomes have to move together. One without the other creates problems for the plan, the member, and the employer. Many pharmacy programs go off track at this point. The basic goals are easy to state, but vendors often make the process feel more complicated than necessary. Complexity becomes a shield. It keeps employers from asking direct questions and makes ordinary oversight feel like specialized work only insiders can understand.

Pharmacy benefits are technical, but the management framework is not complicated. The job is to set clear standards, follow them, measure results, and hold the people managing the program responsible for performance. Most problems begin when expectations are unclear, hidden, ignored, or changed without the plan sponsor understanding the financial impact.

Once a plan sponsor loses visibility into how drugs are selected, approved, dispensed, and monitored, the program becomes harder to govern. Costs rise, exceptions multiply, and HR is left trying to explain decisions to employees without having full control over the process behind those decisions. This creates frustration for members and risk for the employer.

Managing pharmacy benefits does not require making the program more complex. It requires discipline. The plan needs clear goals, sound clinical standards, defined financial expectations, and useful reporting. Without those basics, even the best-looking PBM arrangement can drift away from the employer’s interests.

Start With Appropriate Drug Selection

Once the goals are clear, the work begins with a basic question: was the appropriate medication selected for the patient? The medication should be clinically appropriate, safe, effective, and cost-conscious. It should fit the patient’s diagnosis, history, prior therapy, risk factors, and benefit design. It should also make financial sense for the plan when lower cost therapies can reasonably produce the same or better outcome.

This is where formulary management, prior authorization, step therapy, quantity limits, clinical edits, specialty drug review, and medication policy come into play. These tools are often described in a way that makes them sound cold or restrictive. Poorly designed, they can be. Properly managed, they protect the patient and the plan. Prior authorization should not exist to create friction for the sake of denying care. It should confirm the drug is being used for the right patient, for the right condition, at the right dose, and at the right point in therapy.

Step therapy should not be a game of delay. It should help determine whether a clinically sound, lower-cost option should be tried before moving to a higher-cost therapy. Quantity limits should not be arbitrary. They should reflect safe dosing, FDA labeling, clinical evidence, and common-sense utilization control. Medication policies should not sit in the background where no employer ever sees them. They are the operating standards behind many pharmacy decisions.

Employers do not need to become pharmacists, but they do need to understand how these standards are built, who approves them, how often they are reviewed, and whether they align with the plan’s goals. When drug selection is handled correctly, pharmacy benefits become much easier to manage. When it is handled poorly, everything downstream gets more expensive.

Drug Selection Is a Governance Issue

Many employers focus too much on discounts, rebates, and guarantees while giving too little attention to drug selection. This has it backwards. A large rebate on the wrong drug is not a win. A low ingredient cost on a medication the patient does not need is not a win. A broad formulary with weak clinical controls may feel member-friendly until the plan sees the claims experience. The real question is not whether the PBM claims to manage trend. The real question is whether the PBM can explain, defend, and document how drugs are selected and monitored.

• Why was the medication approved?
• Was a lower-cost option available?
• Was the member previously treated with an alternative?
• Was the dose appropriate?
• Was the prescription filled through the right pharmacy channel?
• Was the drug medically necessary?
• Was there waste, duplication, or a safety concern?

If those questions cannot be answered clearly, the employer does not have a pharmacy strategy. It has a vendor relationship. Drug selection drives more than the pharmacy claim. It affects member experience, medical claims, adherence, safety, employee trust, and the employer’s ability to manage plan assets.

When plan sponsors treat drug selection as a vendor-only function, they give up control over one of the most important cost and quality levers in the health plan. Good governance does not mean the employer makes clinical decisions. It means the employer understands the standards, reviews the results, and holds the administrator responsible for applying them consistently. Fiduciary oversight becomes practical here. It is not about micromanaging clinical judgment. It is about making sure decisions are made in the best interest of the plan and its members, not around hidden economics or vendor convenience.

Make Sure the Patient Takes the Medication

Selecting the appropriate medication is only part of the job. The patient also has to take it. This is where many plans lose money and outcomes suffer. A drug can be properly selected, properly approved, and reasonably priced. None of it matters if the patient does not take it as prescribed.

Medication adherence is especially important in chronic conditions such as diabetes, high blood pressure, high cholesterol, asthma, depression, and other long-term conditions. Poor adherence can lead to avoidable medical claims, emergency room visits, hospitalizations, disease progression, and lower quality of life. Every employer paying medical and pharmacy claims should care about whether members are taking the medications intended to keep them stable because adherence affects total cost and workforce health.

Adherence can be supported through refill reminders, pharmacist outreach, medication therapy management, synchronized refills, 90-day supplies where appropriate, member education, lower-cost alternatives, and benefit designs that remove unnecessary barriers for high-value drugs. It can also be hurt by poor communication, confusing coverage requirements, unaffordable copays, pharmacy disruption, unnecessary prior authorization delays, and designs built around vendor economics instead of patient behavior.

The issue is not simply whether the member filled the drug. The better question is whether the member is likely taking it consistently enough to receive the intended clinical benefit. A paid claim shows access. It does not always show follow-through. A pharmacy program should be measured not only by whether drugs were dispensed, but by whether members stay on the therapies that protect their health and reduce avoidable costs.

Measure What Matters

Employers do not need a dashboard with 200 metrics. They need a smaller set of measures tied directly to cost containment, outcomes, safety, and member experience. The point is not to bury HR, finance, or the benefits team in reports. The point is to make the program manageable and help the employer make better decisions.

For drug selection, the employer should know whether members are using clinically appropriate, cost-effective therapies. Measures such as generic dispensing, specialty utilization, formulary compliance, prior authorization outcomes, appeals, and high cost claim review help show whether the plan is controlling waste without creating unnecessary barriers to care.

For adherence, the employer should understand whether members with chronic conditions are staying on therapy. Proportion of days covered, often called PDC, is a practical measure. A common threshold is 80% adherence, meaning the member had the medication available for at least 80% of the measurement period. Missed therapy often shows up later as higher medical costs, lower productivity, and worse member outcomes.

For safety and financial management, the employer should expect reporting on duplicate therapy, high risk medications, opioid utilization, dose concerns, total cost of care, rebates, member cost share, specialty trend, and plan paid amounts. Good reporting should tell the employer what happened, why it happened, what is being done about it, and whether the action worked.

A lot of vendor reporting falls short here. It may look polished, but it does not always help the employer govern the program. A useful report should create clarity. It should make the employer smarter, not more dependent on the vendor for interpretation.

Do Not Let Complexity Replace Accountability

Pharmacy benefits become complicated when employers allow vendors to set the standards, control the data, interpret the results, and define success on their own terms. Once this happens, the employer stops managing the benefit and starts reacting to the vendor’s version of the story.

Employers do not need a more complicated program. They need a simpler management framework with accountability built into it. Define the goals. Set the standards. Select appropriate therapies. Make sure patients take their medications. Measure cost, outcomes, safety, and member experience. Review exceptions. Hold vendors accountable. Repeat the process.

The details matter, but the framework is straightforward. Employers, brokers, and pharmacy benefit consultants do not need to accept confusion as the price of admission. Pharmacy benefits should not be a black box. They should be governed like any other major plan asset, with clear standards, clear data, and clear accountability.

When employees do not understand why a drug was denied, changed, or delayed, HR owns the frustration even when the vendor made the decision. Pharmacy benefit governance cannot be treated as a back-office function. It affects employee trust, benefit satisfaction, and the employer’s credibility.

Managing pharmacy benefits is not easy, but it is simpler when the plan sponsor refuses to let the program drift away from its core purpose: contain cost, improve outcomes, protect the patient, and protect the plan. Vendors may benefit when the program feels too complicated to challenge. Employers do not.

Once the basics are nailed down, employers and their consultants can move to more advanced strategies, including disease management programs, targeted clinical interventions, and other initiatives designed to improve outcomes. But those efforts work best when the foundation is already in place. Pharmacy benefits do not need more mystery. They need standards, measurement, transparency, and accountability.